Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 108774 - 108774
Published: Dec. 1, 2024
Language: Английский
Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 98 - 98
Published: Jan. 3, 2025
The incidence rate of cutaneous melanoma is on the rise worldwide, due to increased exposure UV radiation, aging populations, and teratogen agents. However, diagnosis more precise, number new cases related improved tools. Despite better early therapies, has remained a significant public health challenge because its aggressive behavior high potential for metastasis. In 2020, constituted approximately 1.3% all cancer deaths that occurred within European Union, thereby highlighting necessity effective prevention, timely diagnosis, sustainable treatment measures, especially as growing occur among younger patients. Melanoma regarded one most inflamed cancers immune cell presence strong response immunotherapy, fueling need development immune-driven innovative treatments. Approved including checkpoint inhibitors (e.g., anti-PD-1 anti-CTLA-4), have notably survival rates in melanoma. limitations PD-1/PD-L1 CTLA-4 axes inhibitors, such low rates, resistance, toxicity, driven continued research advancements strategies. Current clinical trials are exploring various combinations with costimulatory receptor agonists, chemotherapy, targeted other immunotherapies, goal improving outcomes reducing side effects Emerging approaches, adoptive therapy tumor-infiltrating lymphocytes (TILs) oncolytic virotherapy, showing promise. While CAR-T been less successful compared blood cancers, ongoing addressing challenges like tumor microenvironment antigen specificity. This review provides an overview requirement advances these medications, mark step forward management, set bring fresh breath hope
Language: Английский
Citations
1
Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)
Published: Feb. 26, 2025
CircRNAs are critically involved in the development and progression of various cancers. However, their functions mechanisms pancreatic ductal adenocarcinoma (PDAC) remain largely unknown. CircPHF14 (hsa_circ_0079440) was identified through analysis RNA sequencing data from PDAC normal adjacent tissues. The biological circPHF14 were then evaluated using CCK8, EdU, transwell, colony formation, wound healing assays, as well orthotopic xenograft liver metastasis models. interaction between PABPC1, which enhance stability WNT7A mRNA, investigated pull-down, mass spectrometry, Immunoprecipitation (RIP), actinomycin D assays. role EIF4E promoting biogenesis examined RIP, western blotting. In this study, we observed a significant upregulation both clinical samples cell lines. Functionally, enhanced proliferation vitro vivo. Mechanistically, interacted with PABPC1 to stabilize thereby activating Wnt/β-catenin pathway, subsequently upregulated SNAI2 initiated Epithelial-Mesenchymal Transition (EMT) PDAC. Additionally, found bind PHF14 pre-mRNA, facilitating biogenesis. Finally, developed lipid nanoparticle (LNP) formulation encapsulating sh-circPHF14 plasmids confirmed its anti-tumor efficacy patient-derived (PDX) model. EIF4E-mediated stabilizes mRNA via activates growth These findings indicate that holds promise biomarker therapeutic target for
Language: Английский
Citations
1
Small, Journal Year: 2025, Volume and Issue: unknown
Published: March 13, 2025
Abstract Nanovaccines, as a new generation of vaccines, have garnered significant interest due to their exceptional potential in enhancing disease prevention and treatment. Their unique features, such high stability, antigens protection, prolonged retention, targeted delivery lymph nodes, immune cells, tumors, set them apart promising candidates the field immunotherapy. Polymers, with superior degradability, capacity mimic pathogen characteristics, surface functionality that facilitates modifications, serve ideal carriers for vaccine components. Polymer‐based self‐adjuvanted nanovaccines remarkable ability augment responses. The inherent adjuvant‐like properties polymers themselves offer pathway toward more efficient exploitation nanomaterials optimization nanovaccines. This review article aims summarize categorization elucidate mechanisms action adjuvants. Additionally, it delves into advantages limitations polymer‐based management prevention, providing valuable insights design application. comprehensive analysis could contribute development effective tailored wide range diseases.
Language: Английский
Citations
1
iScience, Journal Year: 2025, Volume and Issue: 28(4), P. 112183 - 112183
Published: March 12, 2025
Renal cell carcinoma (RCC), particularly clear RCC (ccRCC), has seen rising incidence and mortality rates. Early detection remains difficult due to nonspecific symptoms, often leading diagnoses at advanced stages unfavorable prognoses. Current treatments, including surgery, targeted therapies, immunotherapies, face limitations such as adverse reactions, drug resistance, immune evasion. This review discusses the role of circular RNAs (circRNAs) their involvement in circRNA/miRNA/mRNA axis during progression. As competitive endogenous (ceRNAs), circRNAs regulate gene expression cellular processes, proliferation, metastasis, apoptosis, resistance. Furthermore, we explore impact on tumor metabolic reprogramming influence microenvironment. We also summarize clinical prospects, challenges, future directions this field. A comprehensive understanding these complex interactions may provide new insights into diagnosis treatment RCC, ultimately overcoming existing challenges improving patient outcomes.
Language: Английский
Citations
0
Oncology Reviews, Journal Year: 2025, Volume and Issue: 19
Published: March 14, 2025
Advancements in personalized neoantigen-based cancer vaccines are ushering a new era oncology, targeting unique genetic alterations within tumors to enhance treatment precision and efficacy. Neoantigens, specific cells absent normal tissues, at the heart of these vaccines, promising direct immune system specifically against tumor, thereby maximizing therapeutic efficacy while minimizing side effects. The identification neoantigens through genomic proteomic technologies is central developing allowing for precise mapping tumor's mutational landscape. Despite advancements, accurately predicting which will elicit strong responses remains challenging due tumor variability complexity interactions. This necessitates further refinement bioinformatics tools predictive models. Moreover, heavily depends on innovative delivery methods that neoantigen presentation system. Techniques like encapsulating lipid nanoparticles using viral vectors critical improving vaccine stability delivery. Additionally, contribute towards achieving Sustainable Development Goal 3.8, promoting universal health coverage by advancing access safe effective treatments. review delves into potential transform treatment, examining both revolutionary advancements ongoing challenges they face.
Language: Английский
Citations
0
Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown
Published: March 28, 2025
Acquired drug resistance is a main factor contributing to cancer therapy failure and high mortality, highlighting the necessity develop novel intervention targets. Circular RNAs (circRNAs), an abundant class of RNA molecules with closed loop structure, possess characteristics including stability, which provide unique advantages in clinical application. Growing evidence indicates that aberrantly expressed circRNAs are associated against various treatments, targeted therapy, chemotherapy, radiotherapy, immunotherapy. Therefore, targeting these aberrant may offer strategy improve efficiency therapy. Herein, we present summary most recently studied their regulatory roles on resistance. With advances artificial intelligence (AI)-based bioinformatics algorithms, could emerge as promising biomarkers targets
Language: Английский
Citations
0
Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217752 - 217752
Published: April 1, 2025
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11256 - 11256
Published: Oct. 19, 2024
The field of cancer immunotherapy has seen incredible advancements in the past decades. mRNA-based vaccines generating de novo T cell responses, particularly against tumor-specific antigens (TSAs), have demonstrated promising clinical outcomes and overcome diverse challenges. Despite high potential neoantigens to provide personalized immunotherapies through their tumor specificity immunogenicity, challenges related scarcity immunogenic neoepitopes prompted continuous research towards finding new tumor-associated (TAAs) broader therapeutic frameworks, which may now learn from genuine successes obtained with neoantigens. As an example, human endogenous retroviruses (HERVs) emerged as alternatives due tumoral expression ability elicit both reactivity B responses associated efficacy existing immunotherapies. This review aims assess status limitations TSA-directed mRNA lessons that can be derived these checkpoint inhibitor studies guide TAA vaccine development. We expect shared cell, CD4 CD8 antigen presentation will key stimulate expansion for tumors do not contain pre-existing tertiary lymphoid structures. When structures are present highly mutated tumors, current checkpoint-based show even immune privileged sites, hold broaden more types stages.
Language: Английский
Citations
2
Cancer Pathogenesis and Therapy, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
Citations
2
Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 108774 - 108774
Published: Dec. 1, 2024
Language: Английский
Citations
0